What's happened
New lawsuits claim GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition. Regulators are reviewing evidence, while manufacturers dispute the claims. Reports cite studies showing mixed results on risk, with the absolute risk remaining very low.
What's behind the headline?
Brief
- GLP-1s are under investigation for a possible link to NAION, an eye-stroke-like condition. The evidence is observational and not definitive.
- Regulators have not issued a universal safety warning; the FDA is reviewing available data, while Europe notes a possible association in product information.
- Experts say the risk, if any, appears very low, but readers should monitor for vision changes after starting therapy.
What this could mean
- If a causal link is established, prescribers may adjust risk discussions and monitoring protocols.
- Patients could face heightened scrutiny around GLP-1 therapies and potential alternatives.
Next steps
- Ongoing studies and regulatory reviews will clarify whether the risk is real and how large it is.
- Clinicians should continue to weigh benefits against potential (unclear) risks for individual patients.
How we got here
The lawsuits allege NAION is connected to GLP-1 medications from Novo Nordisk and Eli Lilly. Authorities are evaluating available data; studies to date have shown mixed results, and warnings vary by region. The cases come as GLP-1 weight-loss and diabetes drugs remain under close scrutiny for safety.
Our analysis
New York Post reports on lawsuits alleging NAION linked to GLP-1 drugs; The Wall Street Journal and The Washington Post provide context on regulatory stances and individual cases; Al Jazeera covers industry implications and company responses.
Go deeper
- How should patients on GLP-1 therapies monitor for eye symptoms?
- What are the current regulatory positions on GLP-1s and NAION across the US and Europe?
- Could these lawsuits affect the availability of GLP-1 medications?
More on these topics
-
European Medicines Agency - State agency
The European Medicines Agency is an agency of the European Union in charge of the evaluation and supervision of medicinal products.
-
Semaglutide - Medication
Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...
-
New York Post - Newspaper
The New York Post is a daily newspaper in New York City. The Post also operates NYPost.com, the celebrity gossip site PageSix.com and the entertainment site Decider.com. The modern version of the paper is published in tabloid format.